Life sciences facing talent crisis as AI and complex therapies reshape industry
Report finds scaling challenges stem from workflow gaps, not technology limitations alone (Issue #355, 1,300 words, 6 minutes)
Good morning, and welcome to the NPC Healthbiz Weekly e-newsletter from the National Pharmaceutical Congress and Chronicle Companies.
As pipelines become more artificial intelligence (AI)-heavy and complexity increases, the demand for life sciences talent is also shifting, pushing organizations to rebuild operating models around data and automation. Deloitte’s 2026 life sciences outlook found that 30% of surveyed leaders identified agentic AI as an influential trend, yet only a minority reported successfully scaling AI in their business. This gap, Deloitte reports, indicates that challenges lie less in technology and more in workflow redesign. Governance and adoption remain critical constraints on AI scaling, increasing demand for capabilities that bridge scientific priorities with data execution and compliant deployment.
On the development side, Deloitte notes that the rise of large molecules, ribonucleic acid platforms, cell and gene therapies, and antibody drug conjugates is reshaping development and manufacturing requirements. The report highlights these advanced complex modalities as growth drivers over the next two to three years, reinforcing the need for more specialized manufacturing capabilities.
In parallel, McKinsey & Company notes that commercial-scale use of AI is driving demand for data scientists and related roles as organizations move beyond experimentation and embed AI across more business functions. McKinsey’s findings emphasize that data quality, governance, and human oversight are critical to scaling AI in pharma operations. The net effect is a shifting talent mix that increasingly combines domain expertise with data, risk, and governance capabilities.
In Canada, biomanufacturing expansion policies are explicitly tied to workforce capacity. Provincial initiatives also position talent as a core constraint. For example, British Columbia’s life sciences and biomanufacturing efforts emphasize developing specialized skills to encourage industry growth. The province supports structured training that combines classroom instruction with hands-on laboratory sessions and placements at bioscience employers through partnerships with industry groups.
According to the Canadian Alliance for Skills and Training in Life Sciences (CASTL), Canadian biomanufacturing employers continue to report skills gaps that emphasize practical, hands-on competencies over theory, particularly in areas such as cleanroom operations, aseptic technique, and regulatory compliance. CASTL’s workforce strategies summary reports that 80% of employers prioritize Good Manufacturing Practices competence and 70% emphasize laboratory proficiency, while noting persistent gaps in job-ready training among new graduates. These training gaps also point to growing demand for hybrid roles that can bridge manufacturing realities and digital implementation efforts.
IQVIA reports that commercial functions are undergoing a parallel restructuring as life sciences companies move from isolated generative AI pilots to integrated deployment across marketing, sales, and market access. The company’s 2025 commercialization white paper describes efforts to align AI across these functions. At the same time, McKinsey’s 2025 State of AI report finds that AI adoption is most commonly reported in information technology, marketing, and sales functions. These trends suggest growing demand for hybrid commercial talent that combines brand and channel strategy with data fluency and privacy-aware execution.
THIS WEEK 02/03/26
Health Canada accepted for review Cipher Pharmaceuticals’ new drug submission for spinosad (Natroba) for the treatment of head lice and scabies.
Eli Lilly Canada announced that pirtobrutinib tablets (Jaypirca) are now approved and available in Canada as monotherapy for the treatment of relapsed or refractory mantle cell lymphoma in adult patients who have previously received at least two lines of systemic therapy, or chronic lymphocytic leukemia/small lymphocytic lymphoma who have received at least two prior lines of therapy.
Ontario Drug Benefit included Takeda Canada’s fruquintinib capsules (Fruzaqla) in the list of drugs eligible for funding through the Exceptional Access Program for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available standard therapies.
Teva Canada announced a new commercialization and supply agreement with Novartis Canada for siponimod (Mayzent), an innovative oral treatment for patients with active secondary progressive multiple sclerosis. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent in Canada.
NOW, LISTEN UP: Mike Cloutier’s leadership journey
In Season 15 of the NPC Podcast, Co-Chairman of BridgeBright Advisors Mike Cloutier discusses leadership at scale, leadership in the current political climate, and the hardware for being a successful leader. Hear him in conversation with podcast hosts Mitch Shannon, Jim Shea, and Mark McElwain.
CANADIAN HEALTHCARE MARKETING HALL OF FAME
The Canadian Healthcare Marketing Hall of Fame awards were established in 2002 to honour healthcare marketers who have contributed to our vocation and inspire others.
More than 100 honourees have been selected during the past 23 years. In the selection committee’s view, they represent a cross-section of the qualities that make our business unique and fulfilling. NPC Healthbiz Weekly will acknowledge past Hall of Fame Honorees over the next few weeks. Nominate a colleague for the 2026 Canadian Healthcare Marketing Hall of Fame by clicking here.
2002 Inductee
Phil Diamond
Toronto
Editor’s note: Phil died in 2012. The Phil Diamond Award for Community Service is presented annually to a worthy recipient at the Canadian Healthcare Marketing Hall of Fame luncheon held during the annual National Pharmaceutical Congress.
“I’ve been around for a long time,” Phil Diamond says, reflecting on the more than 15 years he has spent in healthcare advertising. His foray into the pharma business started in Montreal at Delmar Chemicals, a division of Labatt’s, where he marketed fine chemicals to pharmaceutical companies internationally. Diamond subsequently joined a Montreal-based ad agency and moved to Toronto to open a satellite office there, but in 1981, he established his own agency, and he considers that his most outstanding achievement. The start-up agency began in “a 12-foot by 12-foot subleased office with one telephone and a day-timer at the ready for possible appointments,” he recalls. His most memorable impression of those early years is that he started with a small amount of money–“just enough to last me three months.” He was amazed, he says, that “the first call I made, I was given a project,” which over time developed into a long-term relationship with a major pharmaceutical company.
Over the years, the agency continued to thrive, thanks to his “family” and his “fantastic” client base. “The layout artists, copywriters, printers, and other production suppliers helped us through the tough times, cleared up problems, and listened to our tales of deadline requirements. They contributed mightily to our success,” he says.
Diamond, who sold the company a few years ago, now works as a healthcare consultant specializing in pre-NOC marketing. “I had a great run in the pharmaceutical industry. What wonderful people I met along the way.”
He stays busy in his off-hours as a hospital volunteer in the cardiac rehab area, as a member of the Rotary Club, and as president of his local baseball association. His most notable charitable achievement, bar none, has been The Walk in the Park golf tournament that raises money for sick children. Diamond founded the event 20 years ago and recalled his first tournament, which had only 12 players. “We raised $400 that first year and bought a wheelchair for the Hospital for Sick Children.” Today, the tournament attracts 144 players, many of whom are from the pharmaceutical and healthcare industries and pay a modest fee to participate. Over the last five years, the tournament has raised about $70,000 for the Starlight Children’s Foundation, which grants wishes to terminally and chronically ill children.”
NEXT WEEK
It’s easy to get your no-charge subscription to NPC Healthbiz Weekly. We’ll send each issue to your phone or inbox at 6:00 a.m. sharp each Tuesday.
You are receiving this newsletter because you are a client of Chronicle Companies, attended a National Pharmaceutical Congress live event or webinar, or previously requested a subscription to one of our newsletters. If you no longer wish to subscribe to this newsletter, please email the subject line “Unsubscribe NPC Healthbiz” to health@chronicle.org.
NPC Healthbiz Weekly is published by Chronicle Companies, 701 Ellicott Street, Buffalo, N.Y. 14203. Canadian Office: 1460 The Queensway, Suite 212, Etobicoke, Ont. M8Z 1S4
Mitchell Shannon, Publisher; R. Allan Ryan, Editorial Director; John Evans, Jeremy Visser, Editors; Cristela Tello Ruiz, New Business Development; Amy Elder, Intern.
Content is copyright (c) 2026, Chronicle LifeSci America Corp., except as indicated. Are you interested in contributing to this newsletter or learning about the Chronicle’s services? Please write to us at health@chronicle.org.
Thanks for reading NPC Healthbiz Weekly. Be sure to subscribe to receive new posts directly to your inbox.
Hey, great read as always. You're spot on about the talent shift in life sciences. It's so vital to bridge scientific knowledge with data and AI skills. Realy insightful work!